Japanese Encephalitis Therapeutics Pipeline Analysis, 2017

  • ID: 4435233
  • Report
  • Region: Japan
  • 60 pages
  • P&S Market Research
1 of 3
Japanese Encephalitis Therapeutics Pipeline in 2017:

Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.

Insights on Pipeline Segments:

Shandong Hengye Biotech Co., Ltd., and VABIOTECH, have one drug candidates each in the Phase III stage of development for the treatment of the disease. The clinical studies of the vaccine, Vero cell-derived inactivated, is currently going on in China in the Phase III stage of development for the treatment of Japanese encephalitis.

Maximum Drugs Being Developed as Vaccines:

The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development. Based on molecule type, around 75.0% of the therapeutic candidates are being developed as vaccines, around 13.0% are made as peptide and 12.0% are being developed as small molecule.

Various Collaborations for Japanese Encephalitis Drug Development:

In September 2017, VABIOTECH in collaboration with National Institute of Hygiene and Epidemiology (NIHE), Vietnam, initiated a Phase III, randomized, multi-centered, parallel groups assignment trial to assess the immunogenicity and safety of the JECEVAX in healthy male as well as female children of age between nine to 24 months.

Some of the key players developing drugs for the treatment of Japanese encephalitis include Shandong Hengye Biotech, Co. Ltd., Panacea Biotec Ltd., and Ennaid Therapeutics, LLC.

Japanese Encephalitis (JE) Therapeutics Pipeline Analysis:
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers4.4 Japanese Encephalitis Therapeutics Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

5. Japanese Encephalitis Therapeutics Pipeline Analysis by Phase (2017)
5.1 Phase III: Drug profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Pre-Clinical: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Strategic Development
5.2.4 Designation
5.2.5 Grants
5.2.6 Patent
5.2.7 Technology
5.3 Discovery: Drug profiles
5.3.1 Strategic Development
5.3.2 Designation
5.3.3 Grants
5.3.4 Patent
5.3.5 Technology
5.4 Unknown: Drug profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Clinical Trials
5.4.4 Clinical Results
5.4.5 Strategic Development
5.4.6 Designation
5.4.7 Grants
5.4.8 Patent
5.4.9 Technology
5.5 Inactive: Drug profiles
5.5.1 Pre-Clinical Study
5.5.2 Pre-Clinical Results
5.5.3 Clinical Trials
5.5.4 Clinical Results
5.5.5 Strategic Development
5.5.6 Designation
5.5.7 Grants
5.5.8 Patent
5.5.9 Technology

6. Clinical Trials Analysis
6.1 Clinical Trials by Region for Japanese Encephalitis Therapeutics Pipeline
6.2 Clinical Trials by Trial Status for Japanese Encephalitis Therapeutics Pipeline

7. Competitive Landscape
7.1 Key Players Benchmarking for Japanese Encephalitis Therapeutics Pipeline
7.2 SWOT Analysis of Japanese Encephalitis Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables:

Pipeline Analysis Of Japanese Encephalitis Therapeutics, By Company (2017)
Description Of Phase Iii Drug Candidates
Clinical Trials Of Phase Iii Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Description Of Unkown Drug Candidates
Clinical Trials Of Unkown Drug Candidates
Description Of Inactive Drug Candidates
Companies - At A Glance

List of Figures:

Research Methodology
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Japanese Encephalitis Therapeutics Drug Candidates Under Development (2017)
Japanese Encephalitis Therapeutics Pipeline Split, By Molecule Type (2017)
Japanese Encephalitis Therapeutics Pipeline Split, By Route Of Administration (2017)
Breakdown Of Clinical Trials, By Region
Breakdown Of Clinical Trials, By Trial Status
Key Players Benchmarking
Swot Analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll